Cited 0 time in
Review of cases of patient risk associated with ginseng abuse and misuse
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Paik, Doo Jin | - |
| dc.contributor.author | Lee, Chang Ho | - |
| dc.date.accessioned | 2022-07-15T23:37:47Z | - |
| dc.date.available | 2022-07-15T23:37:47Z | - |
| dc.date.issued | 2015-04 | - |
| dc.identifier.issn | 1226-8453 | - |
| dc.identifier.issn | 2093-4947 | - |
| dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/157590 | - |
| dc.description.abstract | Ginseng has long been used as a functional food or therapeutic supplement and it is empirically known to be safe and nontoxic. During recent decades, a number of in vitro and in vivo experiments, as well as human studies have been conducted to prove the safety of various types of ginseng samples and their components. Clinical trials, case reports, and in vitro and in vivo research articles addressing the safety, toxicity, and other adverse events of ginseng application were selected and reviewed. Patient risks associated with ginseng abuse and misuse such as affective disorder, allergy, cardiovascular and renal toxicity, genital organ bleeding, gynecomastia, hepatotoxicity, hypertension, reproductive toxicity, and anticoagulant-ginseng interaction were reviewed and summarized. There are some cases of patient risk associated with ginseng abuse and misuse depending on patients' conditions although further investigation in more cases is required to clarify these issues. | - |
| dc.format.extent | 5 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | 고려인삼학회 | - |
| dc.title | Review of cases of patient risk associated with ginseng abuse and misuse | - |
| dc.type | Article | - |
| dc.publisher.location | 대한민국 | - |
| dc.identifier.doi | 10.1016/j.jgr.2014.11.005 | - |
| dc.identifier.scopusid | 2-s2.0-84926185058 | - |
| dc.identifier.wosid | 000353663300001 | - |
| dc.identifier.bibliographicCitation | Journal of Ginseng Research, v.39, no.2, pp 89 - 93 | - |
| dc.citation.title | Journal of Ginseng Research | - |
| dc.citation.volume | 39 | - |
| dc.citation.number | 2 | - |
| dc.citation.startPage | 89 | - |
| dc.citation.endPage | 93 | - |
| dc.type.docType | Review | - |
| dc.identifier.kciid | ART001982041 | - |
| dc.description.isOpenAccess | N | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.description.journalRegisteredClass | kci | - |
| dc.relation.journalResearchArea | Plant Sciences | - |
| dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
| dc.relation.journalResearchArea | Integrative & Complementary Medicine | - |
| dc.relation.journalWebOfScienceCategory | Plant Sciences | - |
| dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
| dc.relation.journalWebOfScienceCategory | Integrative & Complementary Medicine | - |
| dc.subject.keywordPlus | KOREAN RED GINSENG | - |
| dc.subject.keywordPlus | ESTROGEN-RECEPTOR-ALPHA | - |
| dc.subject.keywordPlus | PANAX-GINSENG | - |
| dc.subject.keywordPlus | AMERICAN GINSENG | - |
| dc.subject.keywordPlus | OCCUPATIONAL ASTHMA | - |
| dc.subject.keywordPlus | HERBAL MEDICINES | - |
| dc.subject.keywordPlus | IN-VITRO | - |
| dc.subject.keywordPlus | WARFARIN | - |
| dc.subject.keywordPlus | TOXICITY | - |
| dc.subject.keywordPlus | RAT | - |
| dc.subject.keywordAuthor | abuse and misuse | - |
| dc.subject.keywordAuthor | Panax ginseng | - |
| dc.subject.keywordAuthor | patient risk | - |
| dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S1226845314001171?via%3Dihub | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1366
COPYRIGHT © 2024 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
